Rare Immune-Related Adverse Events (irAEs): Approach to Diagnosis and Management
- Author(s)
- Javaid, A; Bennett, C; Rao, A; Spain, L;
- Journal Title
- Pharmaceutical Medicine
- Publication Type
- Review
- Abstract
- Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape across many solid organ malignancies and form part of routine clinical practice in many tumours. As indications for monotherapy, doublet therapy and combination approaches with chemotherapy and targeted agents expand, clinicians must be aware of the wide range of possible immune-related adverse events (irAEs). Common toxicities, including rash, colitis, hepatitis and pneumonitis are well described in the literature, and have established diagnostic and management algorithms. Rarer toxicities, often with an incidence of less than 1%, are less defined. These syndromes can be poorly recognised, may take on a fulminant course and do not have established or evidence-based diagnostic and management strategies. As such, patients may experience increased morbidity, mortality and poorer outcomes, related both to these irAEs as well as how the treatment of these may affect the management of their underlying malignancy. In this review, we aim to explore the incidence, potential biomarkers, pathogenesis, diagnostic work-up and clinical sequelae of a selection of uncommon irAEs, with a focus on myocarditis, neurological and haematologic syndromes. Further prospective research is required to accurately define the incidence and pathogenesis of these conditions, with the aim of increasing clinician awareness of rare irAEs and to assist with a more personalised and mechanism-based approach to these syndromes.
- Publisher
- Springer Nature
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1007/s40290-023-00508-5
- Open Access at Publisher's Site
https://doi.org/10.1007/s40290-023-00508-5- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-02-13 06:41:41
Last Modified: 2024-02-13 06:51:51